Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Pituitary Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1526625

Biochemical Remission, Diagnostic Delays, and Comorbidities of Acromegaly in China: A Large Single-Centre Retrospective Study

Provisionally accepted
Xue Bai Xue Bai Lian Duan Lian Duan Shengmin Yang Shengmin Yang Tingyu Wang Tingyu Wang Yong Yao Yong Yao Meng Zhang Meng Zhang Jingya Zhou Jingya Zhou Shengnan Cui Shengnan Cui Cheng Pang Cheng Pang Yi Wang Yi Wang Huijuan Zhu Huijuan Zhu *
  • Peking Union Medical College Hospital (CAMS), Beijing, China

The final, formatted version of the article will be published soon.

    Introduction: Long-term biochemical nonremission and long-delayed diagnosis can increase the incidence of comorbidities of acromegaly and seriously affect patients’ quality of life. To identify predictors of biochemical remission and quantify the relationship between delayed diagnosis and comorbidities, we performed a retrospective study of a large, single-centre cohort.Methods: This retrospective cohort included 1692 hospitalized patients with acromegaly seen in a single referral centre between 2012 and 2020. To account for the longitudinal data structure, generalized estimating equation (GEE) regression models were established to further evaluate the factors associated with biochemical remission.Results: Overall, 1692 inpatients (55.4% females, mean age at diagnosis: 40.1±12.2 years, mean age at onset: 34.4±11.71 years, median diagnostic delay: 4.4 years) were included. A total of 86.8% (1306/1504) had macroadenomas, and 34.1% (486/1424) had invasive tumours. According to the international diagnostic criteria, the 5-year biochemical remission rate of this cohort was 26.4%, while the Chinese criterion was 41.4%. According to the GEE model, invasion and large adenoma influence biochemical nonremission. After age 50, comorbidities such as hypertension and hyperlipidaemia were considerably more common in females than in males. The proportion of patients with comorbidities among those with a delayed diagnosis ≥4 years was greater than among those with a delayed diagnosis <4 years (54.9 vs. 47.9%, P=0.004).Conclusion: The older the age at diagnosis and the longer the delay in diagnosis, the greater the incidence of comorbidities, especially in elderly females. Appropriate treatment of acromegaly should be started early to achieve biochemical control.

    Keywords: Acromegaly, biochemical remission, Comorbidity, Diagnostic delays, Retrospective study

    Received: 12 Nov 2024; Accepted: 05 Feb 2025.

    Copyright: © 2025 Bai, Duan, Yang, Wang, Yao, Zhang, Zhou, Cui, Pang, Wang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Huijuan Zhu, Peking Union Medical College Hospital (CAMS), Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.